Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 9/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 8/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | DDX3X | O00571 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CCR3 | P51677 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL402604 | 0.91 | MAPK10 (0.38) | MAPK10MAPK8NPSR1HTTMAPK9 | |
| SCHEMBL3204580 | 0.89 | NPSR1 (0.41) | MAPK10MAPK8NPSR1HTTMAPK9 | |
| SCHEMBL2251440 | 0.87 | SMARCA2 (0.39) | MAPK10MAPK8MAPK9MEN1KMT2A | |
| SCHEMBL23573782 | 0.86 | NPSR1 (0.42) | MAPK10MAPK8NPSR1HTTMAPK9 | |
| SCHEMBL2256236 | 0.85 | MAPK10 (0.40) | MAPK10MAPK8NPSR1HTTMAPK9 | |
| SCHEMBL2249160 | 0.85 | MAPK10 (0.40) | MAPK10MAPK8NPSR1HTTMAPK9 | |
| SCHEMBL3208737 | 0.84 | RORC (0.47) | MAPK10MAPK8NPSR1RORCDHODH | |
| SCHEMBL3214027 | 0.84 | RORC (0.47) | MAPK10MAPK8NPSR1RORCDHODH | |
| SCHEMBL3200068 | 0.84 | RORC (0.47) | MAPK10MAPK8NPSR1RORCDHODH | |
| SCHEMBL29714051 | 0.84 | MAPK10 (0.41) | MAPK10MAPK8NPSR1HTTMAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989455-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-08-02 | — | — | US | claimed |
| US-8513257-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INCORPORATED (US) | 2013-08-20 | — | — | US | disclosed |
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | CYTOKINETICS, INC. | 2012-07-05 | — | — | US | disclosed |
| US-8110595-B2 | Ureas and their use in the treatment of heart failure | CYTOKINETICS, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-8101617-B2 | Disubstituted ureas and uses thereof in treating heart failure | AMGEN, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7989455-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172372-A1 | Ureas and Their Use in the Treatment of Heart Failure | TNNI3, TNNT2, MYLK2 | MAPK10 2342/4885MAPK8 3165/4885NPSR1 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.